An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Stargardt Disease Type 1 (STGD1)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Eye & ENT Hospital of Fudan University, Shanghai, China
Contact: Study coordinator (Gezhi Xu) · drxugezhi@163.com · +86 18017316316

Study leads

Study Director
HuidaGene Therapeutics Co., Ltd.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase 1 Study of C.001 in Retinal Degeneration

Geographic Atrophy · Stargardt Disease · RPE-mediated Maculopathy

Abroad (travel likely)RecruitingPHASE1

Beverly Hills, United States

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

Stargardt Disease

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bakersfield, United States · Pittsburgh, United States

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Stargardt Disease · Stargardt Disease 1 · Cone Rod Dystrophy

Abroad (travel likely)Recruiting

San Francisco, United States · Gainesville, United States

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Stargardt Disease · Cone Rod Dystrophy · Juvenile Macular Degeneration

Abroad (travel likely)RecruitingPHASE1, PHASE2

San Francisco, United States · Gainesville, United States